Colorectal Cancer

Data from the phase 3 BREAKWATER trial supported full FDA approval of the encorafenib combination for metastatic CRC with a BRAF V600E mutation, demonstrating significant survival gains.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

To conclude his conversation with AJMC, Jordan Karlitz, MD, outlines clinical, behavioral, and policy strategies to reverse rising CRC deaths in adults aged under 50.

Jordan Karlitz, MD, highlights racial, ethnic, and socioeconomic disparities in rising CRC mortality rates among younger adults, driven by gaps in screening and awareness.

Jordan Karlitz, MD, explains the rise in CRC-related deaths in younger adults, stressing the need for earlier screening and symptom awareness.

Experts underscored that educating clinicians and the public about red flag CRC symptoms could facilitate earlier screening, diagnosis, and treatment.

Patients with psychiatric disorders had higher CRC risk but no increase in CRC-specific mortality.

Young adults with metastatic CRC (mCRC) and low socioeconomic status (SES) face higher 3-year mortality, whereas race was not independently linked with survival.

Amivantamab-vmjw combined with FOLFOX/FOLFIRI delivers encouraging response rates, durable benefit, and manageable safety.

These results were presented during the press briefing ahead of the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

A study shows falling CRLM incidence and improved survival for synchronous disease, with persistent gaps for metachronous metastases.

From cutting-edge AI detection tools to rising incidence in younger adults and threats to free screenings, 2025 brought major shifts in the struggle against colorectal cancer.

High response rates, strong R0 resection, and low severe adverse events with neoadjuvant therapy plus immunotherapy were identified in a rectal cancer study.

From immunotherapy breakthroughs to early-stage scientific advances shaping the next generation of cancer care, these were the top oncology stories from AACR.

A low-energy total diet replacement program before colorectal cancer surgery helped patients lose weight safely, improved certain symptoms, and showed cost-effectiveness.

A study finds no increased risk of arterial dissections or aneurysms among patients with metastatic colorectal cancer treated with angiogenesis inhibitors.

Screening among 45- to 49-year-olds rose nearly 10-fold in hospitals after US guideline updates, but disparities persist.

A study identifies tumor stage and stoma status as key drivers of diminished quality of life among patients with colorectal cancer.

Women under 50 who consume high levels of ultraprocessed foods have a higher risk of developing early-onset conventional colorectal adenomas.

The Colorectal Cancer Alliance expands its $100 million Project Cure CRC with 3 new grants driving innovation and improving patient outcomes.

Total neoadjuvant treatment achieved high complete response and organ preservation rates in patients with stage I rectal cancer, according to a new study.

Higher dietary fiber intake was associated with a reduced risk of moderate to severe diarrhea up to 2 years after diagnosis.

Early-onset colorectal cancer (CRC) increases are linked to neuroendocrine tumor reclassification, not true adenocarcinoma growth.

Removing out-of-pocket costs for follow-up colonoscopy led to an immediate and sustained increase in utilization.

A study reveals disparities by sex, socioeconomic status, and location for colorectal cancer screenings.